Issue Date: May 15, 2017 | Web Date: May 10, 2017
DSM invests $25 million in Amyris
DSM will invest $25 million in the biobased chemicals firm Amyris and may follow with an additional $25 million in funding. DSM says Amyris’s fermentation technology is a good fit for its health, nutrition, and materials businesses, where consumers want products made from sustainable sources.
In the near-term, the two firms will work on health-related products, particularly vitamins and nutritional ingredients. They have an exclusive agreement to develop a low-cost route to vitamin A, which . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society